Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We aimed to assess the efficacy and safety of benralizumab as add-on therapy for patients with severe, uncontrolled asthma and elevated blood eosinophil counts.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

Publisher: Elsevier BV

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): October 29 2016

Volume: 388

Issue: 10056

Affiliations

[1 ] The Lung Centre, Vancouver General Hospital, UBC Institute for Heart and Lung Health, Vancouver, BC, Canada. Electronic address: mark.fitzgerald@vch.ca.

[2 ] Wake Forest School of Medicine, Winston-Salem, NC, USA.

[3 ] McMaster University & St Joseph's Healthcare, Hamilton, ON, Canada.

[4 ] Universitätsmedizin Mainz, Mainz, Germany.

[5 ] National Hospital Organization, Tokyo National Hospital, Tokyo, Japan.

[6 ] Universitätsklinikum Rostock, Rostock, Germany.

[7 ] Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA.

[8 ] University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

[9 ] AstraZeneca, Gaithersburg, MD, USA.

[10 ] AstraZeneca, Cambridge, MA, USA.

[11 ] AstraZeneca, Mölndal, Sweden.

Article

Publisher Item ID: S0140-6736(16)31322-8

DOI: 10.1016/S0140-6736(16)31322-8

PubMed ID: 27609406

SO-VID: 8ca42148-d7d7-44c8-a5bf-bfadc962b7b3

History

Data availability:

Comments

Comment on this article

scite_

Cited by 452

See all cited by